source
- Eli Lilly removes Gaucher disease gene therapy trial from pipeline, citing unmet internal criteriaEli Lilly has announced the removal of a phase 1/2 study testing its GBA1 gene therapy for Gaucher disease type 1. The program was part of the assets acquired when the company bought Prevail Therap…
- Senate probes alleged quid pro quo in Trump administration's easing of kratom and tobacco rulesSenate Finance Committee's top Democrat has opened an inquiry into recent policy changes affecting flavored vaping products and kratom, alleging the Trump administration softened regulations in exc…